141 related articles for article (PubMed ID: 26898618)
1. Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.
Asao T; Fujiwara Y; Sunami K; Kitahara S; Goto Y; Kanda S; Horinouchi H; Nokihara H; Yamamoto N; Ichikawa H; Kohno T; Tsuta K; Watanabe S; Takahashi K; Ohe Y
Lung Cancer; 2016 Mar; 93():77-81. PubMed ID: 26898618
[TBL] [Abstract][Full Text] [Related]
2. Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma.
Okuma Y; Hosomi Y; Takahashi S; Maeda Y; Okamura T; Hishima T
Clin Lung Cancer; 2015 May; 16(3):221-7. PubMed ID: 25468802
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
[TBL] [Abstract][Full Text] [Related]
4. Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Okuma Y; Hosomi Y; Miyamoto S; Shibuya M; Okamura T; Hishima T
BMC Cancer; 2016 Feb; 16():156. PubMed ID: 26915359
[TBL] [Abstract][Full Text] [Related]
5. Genetic profiling of thymic carcinoma using targeted next-generation sequencing.
Shitara M; Okuda K; Suzuki A; Tatematsu T; Hikosaka Y; Moriyama S; Sasaki H; Fujii Y; Yano M
Lung Cancer; 2014 Nov; 86(2):174-9. PubMed ID: 25249426
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.
Okuma Y; Hosomi Y; Takagi Y; Iguchi M; Okamura T; Shibuya M
Lung Cancer; 2011 Dec; 74(3):492-6. PubMed ID: 21665316
[TBL] [Abstract][Full Text] [Related]
7. Surgical treatment and prognosis of thymic squamous cell carcinoma: a retrospective analysis of 105 cases.
Zhao Y; Zhao H; Hu D; Fan L; Shi J; Fang W
Ann Thorac Surg; 2013 Sep; 96(3):1019-24. PubMed ID: 23866799
[TBL] [Abstract][Full Text] [Related]
8. The potency of curative-intent treatment for advanced thymic carcinoma.
Okuma Y; Horio H; Hosomi Y; Watanabe K; Maeda Y; Okamura T; Hishima T
Lung Cancer; 2014 May; 84(2):175-81. PubMed ID: 24646831
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
Katsuya Y; Horinouchi H; Asao T; Kitahara S; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Watanabe S; Tsuta K; Ohe Y
Lung Cancer; 2016 Sep; 99():4-10. PubMed ID: 27565906
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.
Liang Y; Padda SK; Riess JW; West RB; Neal JW; Wakelee HA
Lung Cancer; 2015 Jan; 87(1):34-8. PubMed ID: 25443273
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.
Kossai M; Duchemann B; Boutros C; Caramella C; Hollebecque A; Angevin E; Gazzah A; Bahleda R; Ileana E; Massard C; Vielh P; Soria JC; Besse B
Lung Cancer; 2015 Sep; 89(3):306-10. PubMed ID: 26160757
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy for thymic carcinoma].
Okuma Y
Gan To Kagaku Ryoho; 2012 May; 39(5):702-7. PubMed ID: 22584319
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel for platinum-refractory advanced thymic carcinoma.
Watanabe N; Umemura S; Niho S; Kirita K; Matsumoto S; Yoh K; Ohmatsu H; Goto K
Jpn J Clin Oncol; 2015 Jul; 45(7):665-9. PubMed ID: 25840444
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes with chemotherapy for advanced thymic carcinoma.
Okuma Y; Hosomi Y; Takagi Y; Sasaki E; Hishima T; Maeda Y; Shibuya M; Okamura T
Lung Cancer; 2013 Apr; 80(1):75-80. PubMed ID: 23313005
[TBL] [Abstract][Full Text] [Related]
16. Mutation Profile of Thymic Carcinoma and Thymic Neuroendocrine Tumor by Targeted Next-generation Sequencing.
Sakane T; Sakamoto Y; Masaki A; Murase T; Okuda K; Nakanishi R; Inagaki H
Clin Lung Cancer; 2021 Mar; 22(2):92-99.e4. PubMed ID: 33414055
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma.
Agatsuma T; Koizumi T; Kanda S; Ito M; Urushihata K; Yamamoto H; Hanaoka M; Kubo K
J Thorac Oncol; 2011 Dec; 6(12):2130-4. PubMed ID: 21892103
[TBL] [Abstract][Full Text] [Related]
18. The role of radiotherapy for thymic carcinoma.
Nonaka T; Tamaki Y; Higuchi K; Katoh H; Nakahashi M; Horikoshi H; Takahashi K; Minato K; Sugihara S; Kojima M
Jpn J Clin Oncol; 2004 Dec; 34(12):722-6. PubMed ID: 15640502
[TBL] [Abstract][Full Text] [Related]
19. Thymic carcinoma: 30 cases at a single institution.
Yano M; Sasaki H; Yokoyama T; Yukiue H; Kawano O; Suzuki S; Fujii Y
J Thorac Oncol; 2008 Mar; 3(3):265-9. PubMed ID: 18317069
[TBL] [Abstract][Full Text] [Related]
20. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
